Andrew Brown, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Tulio Bertorini, Mark Bromberg, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Eva L Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Alexandra Linares, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, George Nathaniel, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Lenka Slactova, Paul Wicks, Richard Bedlack
{"title":"ALSUntangled #72: Insulin.","authors":"Andrew Brown, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Tulio Bertorini, Mark Bromberg, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Eva L Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Alexandra Linares, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, George Nathaniel, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Lenka Slactova, Paul Wicks, Richard Bedlack","doi":"10.1080/21678421.2023.2288110","DOIUrl":null,"url":null,"abstract":"<p><p>ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2023.2288110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
